MedTrace Logo

Clinical Trial Scheme of Xinnaoning Capsule

NCT03914131 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2019-04-16

No results posted yet for this study

Summary

This study is a randomized, double-blind, parallel-controlled, multicenter clinical study to evaluate the efficacy and safety of Xinnaoning capsule in the treatment of chronic stable angina pectoris (Qi stagnation and blood stasis syndrome).

Conditions

  • Chronic Stable Angina Pectoris
  • Qi Stagnation and Blood Stasis Syndrome

Interventions

DRUG

Xinnaoning Capsule

Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.

OTHER

Xinnaoning Capsule Simulator

Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.

Sponsors & Collaborators

  • Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER)

    lead INDUSTRY

Principal Investigators

  • Fengqin Xu, Doctor · Xiyuan Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2019-12-31
Completion
2020-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03914131 on ClinicalTrials.gov